Gregor Germer

Gregor Germer

Auto-generated profile, based on publicly available information

Gregor Germer

Freie Universität Berlin, Institut für Chemie und Biochemie, 14195 Berlin, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2024 in The Analyst
Verified
Journal Article
Open access
PDF file
GGGregor Germer
Gregor Germer
LGLeonie Gronbach
Leonie Gronbach
JGJill García-Miller
Jill García-Miller
RBRoberta Balansin-Rigon
Roberta Balansin-Rigon
LGLucie J. Groth
Lucie J. Groth
EREckart Rühl
Eckart Rühl
Sensitive mapping of drugs and drug delivery systems is pivotal for the understanding and improvement of treatment options. Since labeling alters the physicochemical and potentially the pharmacological properties of the molecule of interest, its label-free detection by photothermal expansion is investigated. We report on a proof-of-concept study to map the cetuximab distribution by atomic-force microscopy-based infrared spectroscopy (AFM-IR). The monoclonal antibody cetuximab was applied to a human tumor oral mucosa model, consisting of a tumor epithelium on a lamina propria equivalent. Hyperspectral imaging in the wavenumber regime between 903 cm-1 and 1312 cm-1 and a probing distance between the data points down to 10 x 10 nm are used for determining the local drug distribution. The local distinction of cetuximab from the tissue background is gained by linear combination modeling making use of reference spectra of the drug and untreated models. The results from this approach are compared to principal component analyses, yielding comparable results. Even single molecule detection appears feasible. The results indicate that cetuximab penetrates the cytosol of tumor cells but does not bind to structures in the cell membrane. In conclusion, AFM-IR mapping of cetuximab proved to sensitively determine drug concentrations at an unprecedented spatial resolution without the need for drug labeling.

4 March 2026 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
GGG. Germer
G. Germer
KRK. Rajes
K. Rajes
TOT. Ohigashi
T. Ohigashi
HYH. Yuzawa
H. Yuzawa
NKN. Kosugi
N. Kosugi
EREckart Rühl
Eckart Rühl
Delivery of rapamycin loaded on core-multishell nanocarriers with different architectures supporting redox-induced drug release is investigated on human skin ex vivo by scanning transmission X-ray microscopy (STXM) near the O 1s-absorption edge (520-565 eV). The local concentration of the drug and nanocarriers in skin sections is obtained from linear combination modeling using reference spectra of the drug, nanocarriers, and untreated skin. This allows us to probe selectively rapamycin and nanocarriers as a function of exposure time reaching up to 5 days. Additionally, skin samples were treated with dibenzoyl peroxide (DBPO) to induce oxidative stress and simulate the local redox environment found in skin inflammatory conditions. It is shown that rapamycin and nanocarriers have different penetration profiles, which shed light on the drug transport and release mechanisms. These results make use of high spatial resolution at full chemical selectivity reaching down to 75 nm and are compared to skin penetration of topically applied rapamycin in different formulations. They highlight unique capabilities and the future potential of drug transport by polymeric drug nanocarriers.